Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaG9.0: Precision PRaG Therapy in Elderly Advanced Solid Tumors
NCT06112041Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in solid tumor, sponsored by The Second Affiliated Hospital of Soochow University. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06112041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112041.